Monday September 4, 2017
04 Sep 2017 – Admission and First Day of Dealings on AIM
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA (INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE OF […]
Friday August 18, 2017
18 Aug 2017 – Notification of Intention to Admit Shares to Trading on the Alternat...
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA (INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE OF […]
Tuesday May 9, 2017
09 May 2017 – Destiny Board Member Elected to the Academy of Medical Sciences
Brighton, United Kingdom – 9th May, 2017 – Destiny Pharma, a clinical stage biotech company focused on the development of new anti-microbial drugs, is pleased to announce that one of […]
Thursday April 13, 2017
13 Apr 2017 – Destiny Pharma announces appointment of new CEO
Destiny Pharma announces appointment of new CEO Neil Clark brings extensive leadership experience in clinical stage biopharmaceutical companies, as the Company plans Phase IIb trial for lead asset in potentially […]
Wednesday September 21, 2016
21 Sep 2016 – Momentous Step taken by UN to Fight Antibiotic Resistance welcomed b...
Brighton, UK, 21 September 2016 – Destiny Pharma Ltd welcomes today’s United Nation’s meeting in New York where all 193 nations of the UN will sign a landmark declaration to […]
Monday September 5, 2016
05 Sep 2016 – Press Release: Novel Antibacterial Drug, exeporfinium chloride, Deli...
Brighton, UK, 5 September 2016 – Destiny Pharma Ltd, a leading clinical stage biopharmaceutical company focused on developing antibacterial medicines, today announced the results of a US clinical trial of […]
Thursday May 19, 2016
19 May 2016 – Destiny Pharma Welcomes O’Neill Report on Tackling Antimicrobi...
Final report of Government’s AMR Review calls for $1 billion reward for new drugs. Adoption of this and other recommendations is on the G7, G20 & United Nations main agendas […]
Wednesday November 11, 2015
11 Nov 2015 – Press Release: Destiny Pharma Announces Qualified Infectious Disease...
11th November 2015, Brighton, UK – Destiny Pharma Ltd, a leading, clinical stage biopharmaceutical companyfocused on developing and commercialising antibacterial drug products, today announced that the US Food and Drug […]
Monday May 20, 2013
20 May 2013 – Press Release: Part 2 of NIAID-funded US clinical trial of anti-stap...
Brighton, UK – Clinical stage pharmaceutical company Destiny Pharma today announced the further progression of the Phase I US clinical trial of its lead drug XF-73 to Part 2 of […]
Monday March 26, 2012